Suppr超能文献

Ga-FAPI PET/CT 成像对原发性和复发性胰腺导管腺癌治疗管理的影响。

Impact of Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.

机构信息

Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

J Nucl Med. 2021 Jun 1;62(6):779-786. doi: 10.2967/jnumed.120.253062. Epub 2020 Oct 23.

Abstract

Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early detection and accurate staging are critical to prolonging survival. PDAC typically has a prominent stroma including cancer-associated fibroblasts that express fibroblast activation protein (FAP). FAP is a new target molecule for PET imaging of various tumors. In this retrospective study, we describe the clinical impact of PET/CT imaging using Ga-labeled FAP-inhibitors (Ga-FAPI PET/CT) in 19 patients with PDAC (7 primary, 12 progressive/recurrent). All patients underwent contrast-enhanced CT (ceCT) for TNM staging before Ga-FAPI PET/CT imaging. PET scans were acquired 60 min after administration of 150-250 MBq of Ga-labeled FAP-specific tracers. To characterize Ga-FAPI uptake over time, additional scans after 10 or 180 min were acquired in 6 patients. SUV and SUV values of PDAC manifestations and healthy organs were analyzed. The tumor burden according to Ga-FAPI PET/CT was compared with TNM staging based on ceCT and changes in oncologic management were recorded. Compared with ceCT, Ga-FAPI PET/CT results led to changes in TNM staging in 10 of 19 patients. Eight of 12 patients with recurrent/progressive disease were upstaged, 1 was downstaged, and 3 had no change. In newly diagnosed PDAC, 1 of 7 patients was upstaged, and the staging of 6 patients did not change. Changes in oncologic management occurred in 7 patients. Markedly elevated uptake of Ga-FAPI in PDAC manifestations after 1 h was seen in most cases. Differentiation from pancreatitis based on static imaging 1 h after injection was challenging. With respect to imaging after multiple time points, PDAC and pancreatitis showed a trend for differential uptake kinetics. Ga-FAPI PET/CT led to restaging in half of the patients with PDAC and most patients with recurrent disease compared with standard of care imaging. The clinical value of Ga-FAPI PET/CT should be further investigated.

摘要

胰腺导管腺癌 (PDAC) 是一种高度致命的癌症,早期检测和准确分期对于延长生存时间至关重要。PDAC 通常具有突出的基质,包括表达成纤维细胞激活蛋白 (FAP) 的癌相关成纤维细胞。FAP 是各种肿瘤 PET 成像的新靶分子。在这项回顾性研究中,我们描述了 19 例 PDAC 患者使用 Ga 标记的 FAP 抑制剂 (Ga-FAPI PET/CT) 的 PET/CT 成像的临床影响 (7 例原发性,12 例进展/复发性)。所有患者在 Ga-FAPI PET/CT 成像前均进行了增强 CT (ceCT) 进行 TNM 分期。PET 扫描在给予 150-250MBq Ga 标记的 FAP 特异性示踪剂后 60 分钟进行。为了随时间描述 Ga-FAPI 的摄取情况,在 6 例患者中还进行了 10 或 180 分钟后的额外扫描。分析了 PDAC 表现和健康器官的 SUV 和 SUV 值。根据 Ga-FAPI PET/CT 评估肿瘤负荷,并记录肿瘤学管理的变化。与 ceCT 相比,Ga-FAPI PET/CT 结果导致 19 例患者中的 10 例 TNM 分期发生变化。12 例复发性/进展性疾病患者中有 8 例分期升高,1 例分期降低,3 例无变化。在新诊断的 PDAC 中,7 例患者中有 1 例分期升高,6 例患者的分期不变。7 例患者的肿瘤学管理发生变化。大多数情况下,在注射后 1 小时,PDAC 表现中 Ga-FAPI 的摄取明显升高。基于注射后 1 小时的静态成像来区分胰腺炎具有挑战性。关于多点成像,PDAC 和胰腺炎的摄取动力学呈差异趋势。与标准影像学相比,Ga-FAPI PET/CT 使一半的 PDAC 患者和大多数复发性疾病患者的分期重新得到评估。Ga-FAPI PET/CT 的临床价值应进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f703/8729866/c1bb648575f0/jnm253062absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验